BTRX-246040 explained

BTRX-246040, also known as LY-2940094, is a potent and selective nociceptin receptor antagonist which is under development by BlackThorn Therapeutics and Eli Lilly for the treatment of major depressive disorder (MDD).^{[1] [2] [3]} It has demonstrated proof-of-concept clinical efficacy for depression.^[4] As of 2017, it is in phase II clinical trials for the treatment of MDD. It was also under investigation for the treatment of alcoholism, and similarly reached phase II clinical studies for this indication, but development was discontinued.

See also

• List of investigational antidepressants
• J-113,397
• JTC-801
• SB-612,111

External links

• Web site: BTRX-246040 (LY-2940094) . AdisInsight . Springer Nature Switzerland AG .

Notes and References

1. Web site: BTRX 246040 . AdisInsight . Springer Nature Switzerland AG .
2. Dale E, Bang-Andersen B, Sánchez C . Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs . Biochemical Pharmacology . 95 . 2 . 81–97 . May 2015 . 25813654 . 10.1016/j.bcp.2015.03.011 . free .
3. Yin X, Guven N, Dietis N . Opioids in Depression: Not Quite There Yet. UK Journal of Pharmaceutical and Biosciences . 3 . 1 . 2015 . 12–17 . 10.20510/ukjpb/3/i1/89219. free.
4. Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM . 6 . A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies . Neuropsychopharmacology . 41 . 7 . 1803–1812 . June 2016 . 26585287 . 4869049 . 10.1038/npp.2015.348 .